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Molecular Medicine SelectThe recent generation of induced pluripotent stem (iPS) cells from adult human somatic cells has intensified interest in
cellular therapies for treating human disease. This issue’s Molecular Medicine Select highlights progress in overcoming
barriers to the use of transplanted cells. These achievements include the treatment of sickle cell anemia in mice using
genetically repaired iPS cells, the creation of iPS cells that are less prone to cause cancer, and the transplantation of ge-
neticallymodified skeletal muscle cells to prevent arrhythmia following heart attack inmice. Other recent reports describe
a newmethod to foster the engraftment of transplanted cells and a newmeans to genetically alter human embryonic stem
cells.
Hammering Out a Treatment for Sickle Cell Anemia
The generation of induced pluripotent stem (iPS) cells from adult human fi-
broblasts using a cocktail of four factors has heightened interest in using
these embryonic stem cell-like cells in the therapeutic replacement of dam-
aged tissues. Embryonic stem cells and iPS cells are both pluripotent and
share many of the same characteristics. However, iPS cells represent
a more readily available source of cells for autologous transplantation ther-
apy as they are created by the direct reprogramming of somatic cells. A key
experiment is to show that iPS cells can replace damaged tissues in vivo. In
a dramatic proof of principle, Hanna et al. (2007) have now used iPS cells
generated from autologous skin to treat mice with sickle cell anemia. Hanna
et al. took advantage of a humanized mouse model of sickle cell anemia in
which mouse globin genes are replaced by human genes, including the
sickle cell allele of the b-globin gene (bs). These mice develop many of the
symptoms that characterize the human disease including anemia. The au-
thors created iPS cells from thesemice by transducing adult skin fibroblasts
with retroviruses bearing genes encoding the factors Oct4, Sox2, Klf4, and
c-Myc, an approach previously shown to reprogram somatic cells in mice
and recently in humans. They then used homologous recombination to re-
place the bS allele of the b-globin gene, with the bA allele, which does not
cause disease. Those iPS cells that had the gene defect repaired were al-
lowed to differentiate in vitro to become hematopoietic progenitor cells,
which were then transplanted into irradiated mice carrying the the bS allele.
The transplanted iPS cells not only reconstituted the hematopoietic system, butmarkedly alleviated symptoms of the disease.
Althoughmultiple barriers remain to the application of iPS cells for treating human diseases, this achievementmakes that goal
appear more attainable. A next step may be to show that human iPS cells differentiated to become hematopoietic progenitor
cells in vitro have the potential to reconstitute the hematopoietic system in immunodeficient mice.
J. Hanna et al. (2007). Science. Published online December 6, 2007. 10.1126/science.11152092.
Without c-Myc, Cocktail Still Packs a Punch
Of the four factors in the cocktail that enable direct reprogramming of somatic cells, the
protooncogene c-Myc is the one that has the reputation as a problem child. If c-Myc
becomes reactivated in mice derived from iPS cells, there is an increased risk of the
mice developing tumors. This cancer risk presents an obvious barrier to the therapeutic
use of iPS cells in human patients. In experiments that mitigate this concern, two groups
now show that c-Myc is not an absolutely essential component of the four-factor cock-
tail (Nakagawa et al., 2007; Wernig et al., 2007). Both groups succeed in making iPS
cells frommouse embryonic fibroblasts using only the other three factors in the cocktail:
Oct4, Sox2, and Klf4. In addition, Nakagawa et al. show that the three-factor cocktail
can be used to derive human iPS cells from adult human dermal fibroblasts. Although
the efficiency of iPS generation is lower in the absence of c-Myc, both groups demon-
strate that the mouse iPS cells generated using the three factors can give rise to chime-
ric mice when transplanted into mouse blastocysts. Moreover, Nakagawa et al. show
that chimeric mice generated from iPS cells using this new method did not develop tu-
mors during the study period (4months), unlike mice generated from iPS cells created
using the classical four factor approach. These findings remove another hurdle on the
path toward the use of reprogrammed somatic cells for treating human diseases.
M. Nakagawa et al. (2007). Nat. Biotech. Published online November 30, 2007. 10.1038/nbt1374.
M. Wernig et al. (2007). Cell Stem Cell. Published online December 13, 2007. 10.1016/j.stem.2007.12.001.
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Antibodies Clear Out a Niche for Transplanted Stem Cells
Patients receiving an allogeneic bone marrow transplant must first undergo pretreatment with chemotherapy or irradiation as
part of a marrow ablation regimen to decrease the likelihood of graft rejection. However, these regimens come with serious
side effects. Now, Czechowicz et al. (2007) have established a technique in mice that holds promise for enabling allogeneic
bone marrow transplantation without prior marrow ablation. Their findings may also contribute to ongoing efforts to establish
methods for the engraftment of other types of stem cells in other tissues. The authors devised an approach to selectively de-
plete HSCs resident in the host bone marrow, thereby freeing up the marrow niche to provide a suitable home for the trans-
planted donor HSCs. To do this, they administered an antibody ACK2 that binds to and disrupts signaling by c-kit, a receptor
tyrosine kinase that is a commonly usedmarker of HSCs. They show that administration of the antibody depletes the resident
population of HSCs and dramatically improves the efficacy of donor HSC engraftment. This approach should enable efficient
transplantation of blood forming stem cells from both autologous and allogeneic sources, bypassing the need for prior mar-
row ablation with its attendant side effects.
A. Czechowicz et al. (2007). Science 318, 1296–1299.
Gene Targeting in Human ES Cells Has a ROSA Future
Realizing the therapeutic potential of human embryonic stem (ES) cells is likely to require the
development of techniques to genetically alter them with greater ease and precision, as has
been achieved with mouse ES cells. Irion et al. (2007) have taken a cue from prior work in
mice to successfully target the Rosa26 locus in human ES cells through homologous recom-
bination. In mice, the Rosa26 locus has been shown to promote the ubiquitous expression
of transgenes and has been targeted in ES cells with high efficiency. First, the authors identified
the ROSA26 locus in humans and showed that human ROSA26 mRNA is expressed in all cell
types tested as is the case in mice. Then they used homologous recombination to introduce
a red fluorescent protein (tdRFP) construct into the Rosa26 locus and were able to generate
human ES cells bearing the tdRFP reporter. They show that tdRFP is expressed in both ES cells
and their differentiated progeny and is not subject to gene silencing. Havingmade these ES cell
lines, the authors then show that recombinase-mediated cassette exchange can be used to
replace the tdRFP-encoding cDNA with any cDNA of interest, a facet of this achievement
that is likely to be broadly useful to researchers in the field. Future work might also assess
whether these techniques are equally capable of genetically modifying human iPS cells derived
from adult human fibroblasts.
S. Irion et al. (2007). Nat. Biotech. 25, 1477–1482.
Cx43, an Rx for Arrhythmia
Arrhythmias are frequent and dangerous long-term consequence of heart attacks
(myocardial infarctions). Roell et al. (2007) examined whether transplantation of var-
ious cell types following experimentally induced heart attacks in mice could prevent
the occurrence of ventricular tachycardia, a type of arrhythmia that can lead to sud-
den death. They show that engraftment of embryonic cardiomyocytes in the infarct
region decreases the occurrence of ventricular tachycardia, and show that the ben-
eficial impact is due to improved electrical coupling in the damaged tissue, resulting
in activation of engrafted cells during the heart beat. The improved electrical coupling
correlates with the expression of the gap junction protein connexin 43 (Cx43). In con-
trast to embryonic cardiomyocytes, the engraftment of skeletal myoblasts actually
worsened ventral tachycardia. However, if skeletal myoblasts are genetically engi-
neered to express Cx43, they then are able to reduce the occurrence of tachycardia,
similar to levels observed for engraftment of embryonic cardiomyocytes. Because
skeletal muscle is a readily available tissue source, this work raises the possibility
that genetically modified skeletal muscle might be a source of cells for autologous
transplantation following heart attacks.
W. Roell et al. (2007). Nature 450, 819–824.
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